Recap: Intra-Cellular Therapies Q3 Earnings

Intra-Cellular Therapies ITCI reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM.

Here's what investors need to know about the announcement.

Intra-Cellular Therapies beat estimated earnings by 29.63%, reporting an EPS of $-0.57 versus an estimate of $-0.81.

Revenue was up $49.66 million from the same period last year.

Last quarter the company missed on EPS by $0.16 which was followed by a 5.08% increase in the share price the next day.

Here's a look at Intra-Cellular Therapies's past performance:

Quarter	Q2 2022	Q1 2022	Q4 2021	Q3 2021
EPS Estimate	-0.76	-0.92	-1	-0.92
EPS Actual	-0.92	-0.78	-1.05	-0.95
Revenue Estimate	49.02M	33.65M	25.37M	22.12M
Revenue Actual	55.58M	35.00M	25.67M	22.21M

To track all earnings releases for Intra-Cellular Therapies visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.